Burning Rock to be Added to MSCI China Index
Burning Rock Biotech Limited (NASDAQ: BNR) has announced its inclusion in the MSCI China Index effective May 27, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Burning Rock Biotech Limited (NASDAQ: BNR) has announced its inclusion in the MSCI China Index effective May 27, 2021. This recognition positions Burning Rock as the only NGS-based precision oncology company from China included in the current MSCI semi-annual index review. The company's mission emphasizes the use of next generation sequencing technology to enhance precision oncology, with significant activities in therapy selection testing and cancer early detection.
Positive
- Inclusion in MSCI China Index enhances visibility and credibility.
- Burning Rock is the only NGS-based precision oncology company from China in the MSCI index.
Negative
- None.
Details
News Market Reaction – BNR
The recorded move for BNR in the trading session of this news was +14.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GUANGZHOU, China, May 12, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will be included in the MSCI China Index, effective after the U.S. market close on May 27, 2021. Burning Rock is the only NGS-based precision oncology company from China that has been selected in the current MSCI semi-annual index review.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contact: IR@brbiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.